Taken together, the totality of evidence supports a causal role for interferon pathways in SLE and selected interferonopathies, especially in patients with high baseline IFN signatures, while also emphasizing the tissue-specific and sometimes protective roles of interferons in other contexts. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.